Vancomycin population pharmacokinetics and dosing proposal for the initial treatment in obese adult patients
Frontiers in Pharmacology · 04.06.2024 · 15
DOI: 10.3389/fphar.2024.1364681 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 04.06.2024. Verfasst von Lucie Polášková und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Military University Hospital Prague, Prague, Czechia. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerstvo Zdravotnictví Ceské Republiky, Univerzita Karlova v Praze.
Abstract (Originalsprache)
Aim
The aim of this study was to develop a vancomycin population pharmacokinetic model in adult obese patients and propose covariate-based dosing individualization in order to maximize the achievement of the newly recommended PK/PD target, according to a revised consensus guideline from 2020.
Methods
Therapeutic drug monitoring data from initial vancomycin therapy (first 3 days of treatment) in adult obese (BMI ≥ 30 kg/m 2 ) patients from 2013 to 2022 were analyzed using a non-linear mixed-effects modeling method, and Monte Carlo simulations were then used to find the optimal dosage maximizing the PK/PD target attainment.
Results
A total of 147 vancomycin serum levels obtained from 138 patients were included in the analysis. Based on the covariate model diagnosis among all tested variables, no reliable predictor of vancomycin volume of distribution (Vd) was identified, while clearance (CL) was positively correlated with eGFR and lean body mass. Creatinine-based eGFR predicted vancomycin CL better than cystatin C-based eGFR. The median (interquartile range) value from conditional modes of individual estimates of Vd, CL, and elimination half-life in our population was 74.0 (70.5–75.4) L, 6.65 (4.95–8.42) L/h, and 7.7 (6.0–10.0) h, respectively.
Conclusion
We proposed dosing individualization based on the covariate found in order to maximize the achievement of the newly recommended PK/PD target of the AUC/MIC ratio of 400–600. Clinical pharmacy/pharmacology interventions may lead to an improvement in vancomycin dosing with a reflection in PK/PD target attainment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Military University Hospital Prague, Prague, Czechia.
- Department of Applied Pharmacy, Faculty of Pharmacy, Masaryk University, Brno, Czechia.
- Department of Clinical Pharmacy, Bulovka University Hospital, Prague, Czechia.
- Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia.
Förderung
- Ministerstvo Zdravotnictví Ceské Republiky
- Univerzita Karlova v Praze
Zitieren
APA
Polášková, L., Murínová, I., Gregorová, J., Slanař, O., & Šíma, M. (2024). Vancomycin population pharmacokinetics and dosing proposal for the initial treatment in obese adult patients. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1364681
Vancouver
Polášková L, Murínová I, Gregorová J, Slanař O, Šíma M. Vancomycin population pharmacokinetics and dosing proposal for the initial treatment in obese adult patients. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1364681
BibTeX
@article{Polkov2024,
author = {Polášková, Lucie and Murínová, Irena and Gregorová, Jana and Slanař, Ondřej and Šíma, Martin},
title = {Vancomycin population pharmacokinetics and dosing proposal for the initial treatment in obese adult patients},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1364681}
}
EUVIMED